This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

Since this is a progressive disease, having a COPD treatment plan is key to breathing easier in the long term. COPD is a lung condition that restricts airflow, making breathing more difficult.

Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of U.S. indications up to six ...

Research provides a foundation for further exploration of NK cells for the development of future treatments and therapies for ...

It is important that clinicians are able to stratify disease severity and exacerbation risk in treatment for patients with chronic obstructive pulmonary disease (COPD), says Klaus Rabe ...

Smoking is the most common aetiologic factor. Evidence for the treatment of patients with mild-to-moderate COPD is limited. Here, the authors show that long-term treatment with high-dose N ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD ...

Trinity College Dublin researchers, based at St James’s Hospital have provided important insights into the behaviour and metabolic function of a previously largely unknown, but crucial ‘natural killer ...

Advancements in Diagnostic Technologies and Treatments: Development of technological advancement is one of the key factors enhancing the growth of the COPD diagnosis and treatment industry.

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...

The connection between respiratory infections, chronic diseases like asthma, and the gut microbiome drives research toward ...